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Abstract 
Purpose: To investigate the effect of benzoxime on degradation of articular cartilage in a rat model of 
osteoarthritis (OA), and the mechanism involved. 
Methods: The OA rat model was prepared by injecting monosodium iodoacetate (MIA) intra-articularly 
to Wistar rats. Rats in the treatment group were given benzoxime (5 mg/kg) daily for 21 days through 
the intra-articular route. The animals were then examined for behavioral changes by assessment of 
asymmetry in bearing weight and paw withdrawal threshold of the hind limb. Western blot assay was 
used for the analysis of inflammatory cytokine expressions. 
Results: The expression of P2X purinoceptor 7 receptor (P2X7R) mRNA was significantly elevated in 
the OA rats (p < 0.02). However, benzoxime treatment caused a marked decrease in the level of P2X1-
8R mRNA. Benzoxime treatment also prevented asymmetry in bearing weight, decreased paw 
withdrawal threshold, and inhibited the expressions of interleukin-1β, interleukin-6 and tumor necrosis 
factor-α in plasma and cartilage. Moreover, benzoxime exhibited significant inhibitory effects on the 
expressions of P2X7R, matrix metalloproteinase (MMP)-13 and prostaglandin E2 (PGE2) in cartilage 
tissue. It also significantly suppressed OA-induced increases in the levels of inhibitor of nuclear factor-
κB (NF-κB) kinase (IKK)α, IKKβ, IκBα and NF-κB p65, and blocked OA-induced increases in the 
expressions of P2X7R, MMP-13 and PGE2. 
Conclusion: These results demonstrate that benzoxime prevents cartilage degradation in OA rats by 
targeting NF-κB signaling pathway. Thus, benzoxime possesses clinical and therapeutic potentials for 
the prevention of cartilage degradation in OA. 
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Osteoarthritis (OA), which is characterized by 
alteration in the architecture and composition of 
joints has adverse impact on socio-economic 
development [1, 2]. The symptoms of early-stage 
OA include joint inflammation, edema, stiffness 
and pain, while the advanced stage is 
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© 2018  The authors. This work is licensed under the Creative Commons Attribution 4.0 International License 
 
 
He et al 
436 
 
characterized by deformity of the joints [1,2]. The 
pathological alterations associated with OA are 
articular cartilage degradation, damage to sub-
chondral bone and hyperplasia of the synovium 
[2]. Changes in the equilibrium between 
formation and degradation of cartilage matrix 
components are linked to etiology of bone tissue 
damage [3].  
 
The current treatment for OA involves 
conservative measures like modification of 
lifestyle, physiotherapy, chemotherapy and 
surgery [4]. At the early stage of OA, treatment 
involves symptomatic relief using available 
chemotherapeutic agents, while the advanced 
stage (characterized by irreversible disability of 
joints) requires surgery to relieve pain and 
improve joint function [5]. The development and 
progression of OA are induced by the expression 
of cytokines through alteration in the equilibrium 
between formation and degradation of 
chondrocytes [6]. Up-regulation of interleukin-13 
leads to the breakdown of cartilage matrix and 
affects chondrocyte function [6,7]. The 
chondrocytes and synovial membrane of OA 
patients express higher level of interleukin-1β, 
interleukin-6, tumor necrosis factor-α and 
prostaglandin E2 [8]. 
 
The expression of matrix metalloproteinases 
(which degrade cartilage tissues) is enhanced by 
prostaglandin E2 [9]. The currently-used non-
steroidal anti-inflammatory drugs for OA 
treatment are associated with development of 
complications, while steroidal agents do not 
show satisfactory results [9]. Thus, the need for 
identification of newer and more effective 
chemotherapeutic agents for OA has continued 
to be a challenge to clinicians. Purinergic 
membrane receptor P2X expression in cartilage 
tissues has been shown to be associated with 
the onset of pain in OA patients [10]. The P2X7 
receptor (P2X7R) plays an important role in the 
regulation of joint pain and edema [11]. It has 
been reported that damage to peripheral nerves 
causes up-regulation of P2X7R in macrophages 
[12].  
 
The present study was undertaken to investigate 
the effect of benzoxime on cartilage tissue 







Thirty, 8 – 10-week old male Wistar rats were 
obtained from the Shanghai SLAC Animal Co., 
Ltd., Shanghai. The rats were maintained singly 
in plastic boxes under 12 h light - 12h dark cycle 
at a constant temperature of 24 ˚C and humidity 
of 55 ± 10 %, with ad libitum access to fresh 
water and standard laboratory feed. The rats 
were acclimatized to the laboratory conditions for 
one week before the start of the study. All animal 
experiments carried out according to the 
guidelines of Principles of international laboratory 
animal care [13]. The approval for the study was 
provided by the Research Ethical Committees of 
the Provincial Hospital Affiliated to Shandong 
University (approval no. TKY03331). 
 
Preparation of OA rat model and treatment  
 
Twenty rats exposed to volatile isoflurane 
anesthesia were administered 5 mg/kg MIA 
through the intra-articular route. The rats were 
then assigned to two groups of 10 animals each: 
benzoxime treatment group and model control 
group. The rats in the treatment group were intra-
articularly injected 5 mg/kg benzoxime daily for 
21 days. After analysis of behavioral changes for 
21 days, the rats were sacrificed for western blot, 
enzyme-linked immunosorbent assay (ELISA) 
and quantitative reverse transcription polymerase 




After treatment with benzoxime for 21 days, the 
OA rats were sacrificed by spinal dislocation. The 
limb skin was disinfected to intercept the femur 
5cm from femoral condyle. Subsequently the 
tibia was also dissected below the tibia plateau to 
isolate the knee joint. The tissues around the 
joint were cleaned to expose the articular 
cartilage which was then carefully cut off from the 
joint. The RNA present in the cartilage was then 
isolated by TRIzol reagent (BD Biosciences) in 
accordance with the instructions on the kit 
manual. Samples of the RNA (5 µg samples) 
were subjected to reverse transcription using the 
PrimeScript RT reagent kit (Sigma-Aldrich, St. 
Louis, MO, USA). A mixture of 5X PrimeScript 
buffer (2 µL), PrimeScript RT enzyme mix (0.5 
µL), total RNA (2 µL) and RNase-free dH2O (5 
µL) was incubated at room temperature for 
20min, followed by heating to 85 ˚C for 20 s. 
 
SYBR Premix Ex Taq TM II kit (RR041A; Sigma-
Aldrich) was used for quantitative polymerase 
chain reaction. The cDNA (2 µL) was combined 
with SYBR Premix Ex Taq (12.5 µL), 1 µl each of 
forward and reverse primers, and dH2O (8.5 µL). 
The mixture was subjected to 40 cycles: initially 5 
min at 95 ˚C, then denaturation for 30 sec at 95 
˚C, annealing for 40 sec at 60 ˚C, and extension 
for 30 sec at 72 ˚C. After completion, 71 more 
cycles were performed at 80 ˚C for 30 sec. 
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Subsequently, the temperature was increased by 
0.5 ˚C for each repetition. Protein expression 
was normalized to GAPDH mRNA. The 
expressions of genes were quantified using 
SYBR Green Master mix (Life Technologies, 




Following benzoxime treatment for 21 days, the 
OA rats were examined for asymmetry in bearing 
weight for the hind limb, and their paw withdrawal 
thresholds were evaluated. Asymmetry in 
bearing weight is expressed as the percentage of 
the distribution of weight between left and right 
hind limbs. The reference level was taken as the 
value obtained at the start of treatment. In the 
determination of paw withdrawal threshold, the 
animals were put on a steel wire mesh in an 
organic transparent glass box of dimensions 20 
cm x 20 cm x 30 cm. Von Frey monofilaments 
(58011, Stoelting Co., USA) were employed for 
the measurement of paw withdrawal threshold. 
For each animal, three readings were recorded 
for both hind limbs, and the mean value was 
calculated. The difference between the two hind 
limbs was used to determine paw withdrawal 
threshold. 
 
Analysis of knee edema size 
 
Edema sizes of the knee in the treatment, OA 
and vehicle control groups were determined after 
21 days of treatment. Knee diameter was 
determined with a digital caliper and recorded for 
each rat. The diameter of the left knee was then 
subtracted from that of right knee to obtain the 
knee edema [14]. 
 
Determination of cytokine expressions 
 
Blood samples were collected from the carotid 
artery of the animals under isoflurane 
anesthesia in EDTA phlebotomy blood sample 
bottles (Jiangsu Yuli Medical instruments Co., 
Ltd, China). The blood samples were 
centrifuged for 20 min at 3,500 x g to obtain 
plasma samples which were stored under liquid 
nitrogen atmosphere. Cytokine levels in the 
plasma samples were determined using ELISA 
kits (Santa Cruz Biotechnology Inc., CA, USA) 
as per the manufacturer’s protocol.  
 
Western blot analysis 
 
Sliced cartilage tissues from the treatment, OA 
and vehicle groups of rats were subjected to 
homogenization in TRIzol® (50mg fresh 
weight/mL; Invitrogen, Paisley, UK) in liquid 
nitrogen using a dismembrator (Sartorious, 
Epsom, UK). The tissue homogenates were 
frozen, treated with lysis buffer and centrifuged 
for 10min at 12,000 x g at 4 ˚C to remove the 
sediments. The protein contents of the 
supernatant fractions were determined with BCA 
protein assay kits. Thereafter, protein samples 
(25 - 35 µg) were subjected to electrophoresis on 
12 % sodium dodecyl sulfate-polyacrylamide gel, 
and subsequently transferred to polyvinylidene 
difluoride (PVDF) membranes. Membrane 
blocking was performed for 2h at 36 ˚C using 3 
% non-fat milk.  
 
The membranes were incubated overnight with 
primary anti-bodies at a temperature of 4 ˚C. The 
following primary antibodies were used: P2X7R 
(dilution 1:800; catalog no. P8232; Sigma-
Aldrich), MMP-13 (dilution 1: 1, 000; catalog no. 
sc-2119; BD Biosciences), PGE2 (dilution 1: 1, 
000; catalog no. ab176140; Abscam), IL-1β 
(dilution 1: 500; catalog no. KAC1211; Thermo 
Fischer Scientific), IL-6 (dilution 1: 500; catalog 
no. PHC0066; Thermo Fischer Scientific), TNF-α 
(dilution 1: 500; catalog no. KAC1751), IKKα 
(dilution 1: 600; catalog no. 14A231; Merck), p-
IKKα (dilution 1: 500; catalog no. 16A6; Cell 
Signaling Technology), IKKβ (dilution 1: 1, 000; 
catalog no. SC8330; Santa Cruz), p-IKKβ 
(dilution 1: 400; catalog no. AB55341; Abscam), 
IκBα (dilution 1: 800; catalog no. 2118S; Cell 
Signaling Technology), p-IκBα (dilution 1:500; 
catalog no. 2859; Cell Signaling Technology), 
NF-κBp65 (dilution 1: 600; catalog no. KHO0371; 
Thermo Fischer Scientific), p-NF-κBp65 (dilution 
1: 500; catalog no. 3033; Cell Signaling 
Technology) and GAPDH (dilution 1: 2, 000, BD 
Biosciences). The membranes were washed two 
times with PBS, and incubated for 2h at ambient 
temperature with secondary antibodies 
conjugated with HRP. Visualization of the protein 
bands was achieved using an enhanced 
chemiluminescence detection system. Analysis 
of the densitometric values was done by the use 
of Image-ProPlus 6.0 (Media Cybernetics, Inc., 
Rockville, MD, USA). Normalization was done 




Data are presented as mean ± standard 
deviation (SD) and were analyzed using one-way 
analysis of variance (ANOVA) and Bonferroni 
tests for comparison among more than two 
groups. Comparison between two groups was 
performed using Student's t-tests, with SPSS 
13.0 (SPSS, Inc., Chicago, IL, USA). Differences 
were considered statistically significant at p < 
0.05.  
 





Effect of benzoxime on OA rats  
 
Rats in the control group showed no changes in 
asymmetry in bearing weight and paw withdrawal 
thresholds during the 21 days of study (Figures 1 
A and B). On the other hand, MIA administration 
significantly increased asymmetry in bearing 
weight to 32 % on day 21 (Figure 1 A; p < 0.05), 
and significantly decreased paw withdrawal 
threshold (p < 0.05) on day 21, when compared 
to the control group (Figure 1B). The MIA 
administration also led to a significant increase in 
knee edema within the same period (Figure 1 C; 
p < 0.05). Administration of benzoxime to OA 
rats reversed the effects produced by MIA 
(Figure 1A). Benzoxime administration blocked 
the MIA-induced increases in weight bearing 
asymmetry and increased paw withdrawal 
threshold (p < 0.05). Moreover, benzoxime 
significantly reduced knee edema in the OA rats, 
relative to rats administered MIA alone ((p < 
0.05, Figure 1C). 
 
Benzoxime prevented up-regulation of P2X7R 
expression in OA rats 
 
In the normal rats, the expression of P2X1-8R 
mRNA was slightly higher in cartilage tissues 
when compared to other members of P2X family 
(Figure 1 D). However, the expression of P2X1-
8R mRNA was significantly higher in the OA rats, 
relative to the other members of this family (p < 
0.05, Figure 1 D). Benzoxime treatment of the 
OA rats caused significant decreases in the 
levels of P2X1-8R mRNA, when compared to the 
untreated control group. 
 
Benzoxime inhibited interleukin-1β, 
interleukin-6 and tumor necrosis factor-α 
expressions in OA rat plasma 
 
Analysis of cytokine expression in OA rat plasma 
showed significantly higher levels of interleukin-
1β, interleukin-6 and tumor necrosis factor-α (p < 
0.02). However, intra-articular administration of 
benzoxime to the OA rats prevented the MIA-
induced increases in the expressions of 
interleukin-1β, interleukin-6 and tumor necrosis 
factor-α (Figure 2). 
 
Benzoxime inhibited expressions of 
cytokines in the cartilage tissues of OA rats 
 
Western blot analysis showed significantly higher 
expressions of interleukin-1β, interleukin-6 and 
tumor necrosis factor-α in cartilage tissues of OA 
rats, when compared to the normal rats (Figure 
3). The expressions of interleukin-1β, interleukin-
6 and tumor necrosis factor-α in the cartilage 
tissues of OA rats were markedly down-regulated 







Figure 1: Effect of benzoxime on behavioral changes 
and expression of P2X1-8R mRNA in OA rats. (A) OA 
rats showed increase in asymmetry of bearing weight 
which was prevented by benzoxime administration. (B) 
In OA rats, benzoxime increased paw withdrawal 
thresholds and (C) inhibited edema formation. *p < 
0.02, untreated vs. normal; #p < 0.05, treatment group 
vs. untreated. (D) Benzoxime treatment for 21 days 




Figure 2: Effect of benzoxime on cytokine expression 
in OA rats. After 21 days of treatment, the levels of 
interleukin-1β, interleukin-6 and tumor necrosis factor-
α in the rat plasma were examined by ELISA. 
Benzoxime treatment inhibited the OA-induced up-
regulation of cytokines in the plasma. *p < 0.02, 
untreated vs. normal; #p < 0.02, treatment vs. 
untreated 
 





Figure 3: Effect of benzoxime on the expressions of 
pro-inflammatory factors in the cartilage tissues of OA 
rats. The cartilage tissues of OA rats contained higher 
levels of interleukin-1β, interleukin-6 and tumor 
necrosis factor-α. Treatment of OA rats with 
benzoxime for 21 days inhibited OA-mediated up-
regulation of these cytokines 
 
Benzoxime inhibited P2X7R, matrix 
metalloproteinase-13 and PGE2 expressions 
in OA rats 
 
The expressions of P2X7R, matrix 
metalloproteinase-13 and PGE2 in the cartilage 
tissue were significantly higher in OA rats than in 
normal control rats (p < 0.05, Figure 4). 
However, benzoxime treatment exerted inhibitory 
effects on the expressions of these proteins 
(P2X7R, matrix metalloproteinase-13 and PGE2) 
in the cartilage tissues of OA rats (Figure 4). 
Significant decreases in the expression of 
P2X7R, MMP-13 and PGE2 were also observed 
in OA rats administered helenalin, a nuclear 




Figure 4: Effect of benzoxime treatment on the 
expressions of PGE2, MMP-13 and P2X7R expression 
in cartilage tissues of OA rats 
 
Effect of benzoxime on the expressions of 
IKKα, IKKβ, IκBα, NF-κB p65 in OA rats 
 
Results from western blot assay showed 
significant increases in the expressions of IKKα, 
IKKβ, IκBα, and NF-κB p65 in the cartilage 
tissues of OA rats (Figure 5; p < 0.05). The 
expressions of activated IKKα, IKKβ, IκBα and 
NF-κB p65 were significantly increased in the OA 
rats, when compared to normal rats. However, 
benzoxime administration to OA rats suppressed 
the increases in the levels of IKKα, IKKβ, IκBα 




Figure 5: Effect of benzoxime on the expressions and 
phosphorylation of IKKα, IκBα NF-κBp65 and IKKβ in 
OA rats. The expressions and activation of these 
molecules were significantly enhanced in OA rats, but 




It has been reported that inhibition of the 
expression of inflammatory cytokines prevents 
the decomposition of cartilage tissues [15]. The 
characteristic features of OA include knee joint 
edema, decomposition of cartilage, hyperplasia 
of synovium and degradation of sub-chondral 
bones [16]. Various cytokines such as nitric 
oxide, PG, interleukin-1β, tumor necrosis factor-
α, interleukin-6 and interleukin-8 are expressed 
in higher proportions in the chondrocytes of OA 
patients [6,9]. Chondrocytes play an important 
role in the onset of pain during inflammation by 
activating the neurons [7,16]. Studies have 
demonstrated that the expressions of interleukin-
4, tumor necrosis factor-α, interleukin-6, and 
interleukin-13 are promoted by P2X7R activation 
[17]. 
 
Down-regulation of tumor necrosis-α also leads 
to longer inhibition of inflammation [18]. It has 
been observed that P2X7R is linked to 
inflammation of knee joints and development of 
OA [10]. The current study has demonstrated 
that pain associated with OA in rats can be 
successfully suppressed by treatment with 
benzoxime. In addition, edema formation in the 
OA was prevented by treatment with benzoxime 
through inhibition of inflammatory processes. It 
was also demonstrated that in OA rats the 
expression of P2X1-8R mRNA was significantly 
higher and that of other members of P2X 
receptors.  
 
Benzoxime administration blocked MIA-induced 
increases in asymmetry in bearing weight and 
decreased paw withdrawal threshold. In addition, 
benzoxime administration to OA rats significantly 
prevented knee edema, when compared to rats 
He et al 
440 
 
administered MIA alone. In OA patients 
benzoxime exhibits inhibitory effect on 
inflammation, and PGE2 upregulates 
degradation of cartilage by promoting the 
expressions of matrix metalloproteinases [9]. The 
level of matrix metalloproteinase-13 expression 
in OA patients is considered to be a reliable 
indicator of the extent of degradation of cartilage 
[19]. 
 
The expression of metalloproteinase-13 was 
significantly higher in the OA but was inhibited by 
treatment with benzoxime. It has been reported 
that the expression of interleukin-1β in the 
chondrocytes causes activation of NF-κB 
pathway [20]. Studies have also revealed that the 
NF-κB signaling pathway is activated by 
expression of P2X7R in OA patients [21]. In the 
present study, the activation of IKKα, IKKβ, IκBα, 
NF-κB p65 was promoted in OA rats. However, 
treatment of the OA rats with benzoxime 
prevented up-regulation of these molecules. The 
inactive form of NF-κB exists in the cytoplasm 
and on activation by P2X7R the molecule enters 
the nucleus [22]. This study has demonstrated 
that expression of P2X7R, matrix 
metalloproteinase-13 and PGE2 in the cartilage 
tissues of OA rats were significantly higher than 
their corresponding levels in normal rats.  
 
Administration of benzoxime exhibited inhibitory 
effects on the expression of P2X7R, matrix 
metalloproteinase-13 and PGE2 in the cartilage 
tissues of OA rats. Western blot assay showed 
that the expression of IKKα, IKKβ, IκBα, NF-κB 
p65 were increased in the cartilage tissues of OA 
rats. The expressions of activated IKKα, IKKβ, 
IκBα and NF-κB p65 were increased significantly 
in the OA rats, relative to normal rats. However, 
benzoxime administration suppressed the 
increased levels of IKKα, IKKβ, IκBα and NF-κB 




The findings of the current study demonstrate 
that benzoxime prevents cartilage degradation in 
OA rats through targeting NF-κB signaling 
pathway. This implies that benzoxime possesses 
clinical and therapeutic potential for the 
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